Corporate News

Corporate News

2024

2024

2024/07/01

Announcement of new structure

2024/02/13

Notice of Consolidation of Shares, Abolition of the Provision of Shares Constituting One Share Unit, and Partial Amendment to the Articles of Incorporation

2024/02/13

Notice Regarding Cancellation of Treasury Shares

2024/02/13

The 3rd Quarter of Fiscal 2023 Financial Statements

2024/01/16

Notice Regarding the Results of the Tender Offer by Otemon Co., Ltd. for the Company Shares Etc. and Change of the Parent Company and the Largest Shareholder Among the Major Shareholders

2024/01/16

Launch of Nanozora® 30mg Autoinjector for S.C. Injection

2023

2023

2023/12/01

Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for NanozoraⓇ

2023/11/24

Announcement of Implementation of MBO and Recommendation for Tender Offer

2023/11/24

Announcement of Revision of Dividend Forecast for the Fiscal Year Ending March 31, 2024 (No Dividend)

2023/11/10

The 2nd Quarter of Fiscal 2023 Financial Statements

2023/11/10

Reference Data of The 2nd Quarter of Fiscal 2023 Financial Statements

2023/08/07

Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

2023/08/04

The 1st Quarter of Fiscal 2023 Financial Statements

2023/08/04

Reference Data of The 1st Quarter of Fiscal 2023 Financial Statements

2023/08/01

Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan

2023/06/29

Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

2023/06/29

Notice of Resolution at the 12th Ordinary General Meeting of Shareholders

2023/06/21

Taisho Pharmaceutical and Biolinq Announce Strategic Collaboration and Exclusive License Agreement in Japan

2023/05/11

Financial Statements for Fiscal 2022

2023/05/11

Reference Data of Financial Statements for Fiscal 2022

2023/02/09

The 3rd Quarter of Fiscal 2022 Financial Statements

2023/02/09

Reference Data of The 3rd Quarter of Fiscal 2022 Financial Statements

2023/02/09

Notice of Revision of Forecasts for the Fiscal Year Ending March 31, 2023

2022

2022

2022/12/01

Launch of Nanozora® 30 mg Syringes for Subcutaneous Injection

2022/11/24

Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan

2022/11/10

The 2nd Quarter of Fiscal 2022 Financial Statements

2022/11/10

Reference Data of The 2nd Quarter of Fiscal 2022 Financial Statements

2022/09/28

Notification of Application for Approval to Manufacture and Market Rheumatoid Arthritis Therapy Nanozora® 30mg Autoinjectors for S.C. Injection in Japan

2022/09/26

Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic

2022/08/05

Cetylpyridinium chloride hydrate (CPC) confirmed to have an action of inactivating SARS-CoV-2 variants

2022/08/03

The 1st Quarter of Fiscal 2022 Financial Statements

2022/08/03

Reference Data of The 1st Quarter of Fiscal 2022 Financial Statements

2022/07/29

Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

2022/05/13

Financial Statements for Fiscal 2021

2022/05/13

Reference Data of Financial Statements for Fiscal 2021

2022/04/14

Former All Blacks players Richard McCaw and Daniel Carter appointed Lipovitan Ambassadors

2022/02/01

The 3rd Quarter of Fiscal 2021 Financial Statements

2022/02/01

Reference Data of The 3rd Quarter of Fiscal 2021 Financial Statements

2021

2021

2021/12/20

Data from Japan's First Phase II/III Clinical Trial of NANOBODY® Ozoralizumab for Rheumatoid Arthritis Presented at the 36th Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research

2021/11/09

The 2nd Quarter of Fiscal 2021 Financial Statements

2021/11/09

Reference Data of The 2nd Quarter of Fiscal 2021 Financial Statements

2021/10/25

Cetylpyridinium chloride hydrate (CPC) confirmed to have an action inactivating SARS-CoV-2

2021/10/08

Taisho Pharmaceutical appointed as Premium Global Partner of New Zealand Rugby

2021/08/05

The 1st Quarter of Fiscal 2021 Financial Statements

2021/08/05

Reference Data of The 1st Quarter of Fiscal 2021 Financial Statements

2021/06/30

Taisho and Ancora Bio sign exclusive license agreement for the development, manufacturing, and commercialization of selective vasopressin V1b receptor antagonist, TS-121, worldwide

2021/06/29

Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

2021/06/24

Taisho Pharmaceutical appointed as Official Supplier of Rugby World Cup France 2023

2021/05/14

Notice Concerning the Execution of the Share Exchange Agreement to Make Biofermin Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.

2021/05/14

Financial Statements for Fiscal 2020

2021/05/14

2021/03/22

Notification of Application for Approval to Manufacture and Market Anti-TNFα multivalent NANOBODY® compound (ozoralizumab) in Japan Japan's first NANOBODY® Therapeutic

2021/02/22

Notification of Application for Approval of Manufacturing and Marketing for Orally Disintegrating Films of SGLT2 Inhibitor Lusefi® Tablets

2021/02/04

The 3rd Quarter of Fiscal 2020 Financial Statements

2021/02/04

2021/01/22

Taisho and Chugai Terminate the Co-Marketing Agreement of Edirol®,a Treatment for Osteoporosis

2020

2020

2020/10/29

The 2nd Quarter of Fiscal 2020 Financial Statements

2020/10/29

2020/08/31

Notice Concerning the Termination of the Agreement Between Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. on the Distribution of Prescription Drugs of Biofermin Pharmaceutical Co., Ltd.

2020/08/06

Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

2020/06/26

Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

2020/05/14

Financial Statements for Fiscal 2019

2020/05/14

2020/04/30

Taisho and BioAge sign exclusive license agreement for the development, manufacturing, and commercialization of hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, TS-143, worldwide

2020/02/14

Financial Statements for the 3rd Quarter of Fiscal 2019

2020/02/14

2020/02/14

Notice of Revision of Forecasts for the Fiscal Year Ending March 31, 2020

2020/01/30

Notice of Postponement of Announcement of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020